Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01576666 · ClinicalTrials.gov registry record · Phase 1
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
A Phase 1 study of Gastric Cancer and Advanced Solid Tumors, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT01576666 is a Phase 1 study of Gastric Cancer and Advanced Solid Tumors that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 120 participants, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT01576666, a Phase 1 study of Gastric Cancer and Advanced Solid Tumors, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies. This study will also learn more about how the combination of these two investigational drugs may work for patients with certain cancers (specifically metastatic breast cancer, advanced pancreatic adenocarcinoma, metastatic colorectal cancer and recurrent glioblastoma multiforme).
Conditions Studied
Interventions
- DRUG LDE225
- DRUG BKM120
Study Locations (20)
Texas
- Texas Oncology Midtown Texas Oncology - Dallas
- Sammons Cancer Center - Texas Oncology SC-2 - Dallas
- University of Texas/MD Anderson Cancer Center SC-3 - Houston
California
- Cedars Sinai Medical Center SC - Los Angeles
- University of California San Francisco UCSF (SC) - San Francisco
Oregon
- Willamette Valley Clinical Studies Williamette Valley Cancer - Eugene
- Northwest Cancer Specialists Northwest Cancer - Portland
Other
- Novartis Investigative Site - Wilrijk
- Novartis Investigative Site - Essen
Florida
- H. Lee Moffitt Cancer Center & Research Institute Moffitt 4 - Tampa
Massachusetts
- Dana Farber Cancer Institute Dana SC - Boston
Minnesota
- Mayo Clinic - Rochester Division of Hematology - Rochester
North Carolina
- Duke University Medical Center Duke - Baker - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2012-07 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01576666
The ClinicalTrials.gov registry entry for NCT01576666 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (62% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which LDE225 is the first listed.
NCT01576666 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Texas, California, Oregon.
Frequently Asked Questions
What is clinical trial NCT01576666 about?
NCT01576666 is a clinical study titled "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors". The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies. This study will also learn more about how the combination of these two investigational drugs may work for patients with c...
What is the current status of trial NCT01576666?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2012-07. Estimated completion is 2015-04.
What conditions does trial NCT01576666 study?
This clinical trial studies the following conditions: Gastric Cancer, Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Gastroesophageal-junction Cancer.
What interventions are being tested in trial NCT01576666?
The interventions under investigation include: LDE225 (DRUG), BKM120 (DRUG).
Who is sponsoring clinical trial NCT01576666?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01576666 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.